fbpx
QQQ
+ 0.48
327.63
+ 0.15%
DIA
-0.36
310.14
-0.12%
SPY
-0.79
385.33
-0.21%
TLT
-0.29
153.96
-0.19%
GLD
-0.43
174.46
-0.25%

What Investor's Should Expect from Portola Pharmaceutical's Additional Upcoming Data Readouts

by
January 9, 2015 12:43 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
What Investor's Should Expect from Portola Pharmaceutical's Additional Upcoming Data Readouts

Portola Pharmaceuticals (PTLA) is a biopharmaceutical company that focuses on discovering and marketing therapies for thrombosis and other hematologic diseases. The company’s three developmental products include Betrixaban, Andexanet alfa, and Cerdulatinib.

Andexanet alfa is in Phase 3 trials and is partnered with Pfizer (PFE), Bayer (BAYN), Bristol-Myers Squibb (BMY), Johnson and Johnson (JNJ), and Daiichi-Sankyo. Portola is also partnered with Biogen for a syk-selective inhibitor inflammatory drug.

Today, Portola announced that its Phase 3 ANNEXA-R study of Andexanet alfa and Xarelto met primary endpoints. The company will present these results at the American College of Cardiology meeting on March 16 at 2:30 P.M. EST.

On January 6, the company announced that they will also be holding a corporate presentation. The presentation is scheduled for January 12 at 3 P.M. EST. This coincides with the J.P. Morgan Healthcare conference.

Portola has several additional data point readouts in 2015.

In early 2015 Portola will announce a futility analysis for a Phase 3 trial for Betrixaban. Topline data is expected to be reported in the middle of 2015.

For Andexanet alfa, Portola will also announce Phase II data (Savaysa reversal), Part 2 of ANNEXA-A Phase 3 with Elliquis, and Part 2 of ANNEXA-R Phase 3 with Xarelto. For all of these studies the FDA has agreed to an accelerated approval pathway.

On November 17, Portola, Bristol-Myers Squibb, and Pfizer announced positive results from Part I of the Phase 3 ANNEXA-A trial with Eliquis.

At the upcoming conference, expect an update on these clinical trials.


Related Articles

What Investor's Are Expecting Ahead of Multiple Nektar Therapeutics Catalysts